

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 23:00 local time 04th of January 2021

Situation Report No. 211 - Kingdom of Saudi Arabia
05th of January, 2021




	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	83,910,386	1,839,660	5,000,203	122,472
New	583,907	7,957	22,351	411

Kingdom of Saudi Arabia

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	363,155	354,609	6,256	2,290	347	11,134,877
New	94	166	10	-	-	31,689


HIGHLIGHTS

- Regions with the highest new infections: Riyadh (34), Makkah (28), Eastern (15), Madinah (6), Nothren Borders (3), Al Jouf (2), Najran (2), and Tabuk (1).
- Saudi Arabia to reopen airspace and land borders to Qatar starting from Monday evening Jan. 4, 2021
- MoH's press conference will be held on Thursday instead of Sunday only this week instead at the Vaccines Center in Riyadh, it will return on time as usual next week.
- Saudi CDC launched the interim guidelines for the use of SARS-CoV-2 vaccine, see link.
- WHO Published guidance on COVID-19 Global Risk Communication and Community Engagement Strategy, see link.
- WHO produces a prepared draft by the SAGE on Immunization Working Group on COVID-19 vaccines.



IMPORTANT LINKS


- MoH COVID-19 updates: <https://twitter.com/saudimoh>
- WHO's COVID-19 global situation reports: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- WHO's COVID-19 dashboard: <https://covid19.who.int/>
- MoH COVID-19 dashboard: <https://covid19.my.gov.sa/ar/Pages/default.aspx>
- CDC's Interim guidelines for the use of SARS-CoV-2 vaccine: <https://covid19.cdc.gov.sa/professionals-health-workers/interim-guidelines-for-the-use-of-sarscov-2-vaccine/>
- WHO guidance on COVID-19 Global Risk Communication and Community Engagement Strategy: <https://www.who.int/publications/i/item/covid-19-global-risk-communication-and-communityengagement-strategy>
- Draft on Immunization Working Group on COVID-19 vaccines: <https://www.who.int/publications/i/item/mrna-vaccines-against-covid-19-pfizer-biontech-covid19-vaccinebnt162b2>



IMPORTANT DEFINITIONS

WHO issues its first emergency use validation for a COVID-19 vaccine

The World Health Organization listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO. This opens the door for countries to expedite their own regulatory approval processes to import and administer the vaccine. Regulatory experts convened by WHO from around the world and WHO's own teams reviewed the data on the vaccine's safety, efficacy and quality as part of a risk-versus-benefit analysis. Experts from individual national authorities are invited to participate in the review. The review found that the vaccine met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the vaccine to address COVID-19 offset potential risks. The vaccine is also under policy review to formulate vaccine specific policies and recommendations for this product's use in populations.



IMPORTANT CONTACTS

- The National Focal Person for COVID-19 is Dr Abdullah Asiri, Assistant Deputy for Preventive Health, MoH, email: AbdullahM.Asiri@moh.gov.sa